News

FDA approves budesonide rectal foam for distal UC


 

References

A rectal foam formulation of 2% budesonide has been approved by the Food and Drug Administration for treating distal ulcerative colitis, the manufacturer, Salix Pharmaceuticals, has announced.

The approved indication is for the induction of remission in patients with mild to moderate distal ulcerative colitis extending up to 40 cm from the anal verge. The foam is administered rectally and “overcomes treatment limitations associated with currently approved therapies which are often ineffective due to insufficient distribution of active drug to the distal colon,” the company said in a statement announcing the final approval on Oct. 8.

The company will be marketing the product as Uceris.

The company also markets budesonide oral extended-release tablets under the same name.

emechcatie@frontlinemedcom.com

Recommended Reading

Probiotics for colic? A PURL update
MDedge Family Medicine
Timing of gluten introduction in infancy doesn’t matter
MDedge Family Medicine
Duodenoscopes transmitted resistant E. coli to 39 patients
MDedge Family Medicine
VIDEO: New drug shows efficacy in metastatic CRC
MDedge Family Medicine
Efficacy, not tolerability, of bowel prep is primary
MDedge Family Medicine
Unplanned hospitalizations common among elders with gastrointestinal cancers
MDedge Family Medicine
FDA approves hepatitis C combination pill
MDedge Family Medicine
Early data find frozen fecal capsules effective for C. difficile
MDedge Family Medicine
Fidaxomicin appears safe, effective for CDAD in children
MDedge Family Medicine
IBD, especially Crohn’s disease, linked to cervical neoplasia
MDedge Family Medicine